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Randomized controlled clinical trials (RCTs) and systematic reviews of RCTs serve a pivotal role in informing evidence-
based practice through guidelines and shared 
decision making (Williams and Dellavalle, 
2012). Although some innovations such as adap-
tive designs have emerged (Kunz et al., 2014; 
Parmar et al., 2014), the basic design of a clini-
cal trial has remained largely unchanged since 
the first trials of streptomycin for tuberculosis in 
1948 (Crofton, 2006), especially with regard to 
the fundamental methods designed to reduce 
bias. Thus, randomization that is truly random 
and concealed from investigators serves to 
reduce selection bias. Blinding the intervention 
and ensuring that each treatment group is fol-
lowed up in the same way reduces performance 
bias. Assessing the outcome in a blinded fash-
ion reduces detection bias, and analyzing all 
those that were originally randomized through 
an intention-to-treat principle minimizes attri-
tion bias (Higgins and Green, 2011). Knowing 
how to critically appraise a clinical trial is a core 
competency for clinical dermatologists and sci-
entists interested in evidence-based medicine 
(Williams, 2011). 
Here, we provide some useful tips on how 
to play your cards right when submitting your 
trials to this journal. Although the Journal of 
Investigative Dermatology does not publish 
many RCTs compared to some clinical derma-
tology journals (Williams, 2014), our output 
has steadily increased (10 in the past five years 
compared with 6 in the five preceding years and 
two in the five years before that), and the JID 
has also published several systematic reviews 
dealing with methodological issues pertinent to 
designing good clinical trials (see, for example, 
Do-Pham et al., 2014). The RCTs that the JID 
does publish are well reported, thanks to our 
early adoption of the recommendations of the 
International Committee of Medical Journal 
Editors for prospective trial registration (Williams 
and Stern, 2005), structured abstracts (Williams 
and Bergstresser, 2010), and complete reporting 
(Williams and Goldsmith, 2006) according to 
the Consolidated Standards of Reporting Trials 
Statement (CONSORT) (http://www.consort-
statement.org). These principles can seem to be 
annoying obstacles, so it is worth revisiting their 
purpose through analogies to the basic rules of 
playing cards (Figure 1).
Rule 1: place your bet
Sadly, despite the potential of clinical trials to 
minimize bias, history is replete with examples 
of distortion of the scientific record (Chalmers 
and Glasziou, 2009; Goldacre, 2012). A particu-
lar source of bias that besets clinical trials—and 
any experimental investigation, for that matter—
is selective highlighting of results that look good 
and downplaying or not reporting those that look 
unimpressive (Chan and Altman, 2005). It was 
previously easy to get away with such selective 
reporting outcome bias because only the investi-
gators knew what their original plan and primary 
outcome or definition of “success” were. This 
problem has been unearthed in all branches of 
medicine and surgery, including dermatology. In 
a survey of 109 RCTs of atopic dermatitis treat-
ment identified through the Global Resource 
of Eczema Trials (GREAT), only 34 had been 
registered on an approved register, and only 19 
of these had been registered properly, that is, 
before recruitment starts and by declaring their 
main success criteria beforehand (Nankervis 
et al., 2012). Only 5 of the 109 RCTs provided 
enough information to allow confidence that the 
main reported findings were consistent with the 
original registration. Prospective trial registra-
tion overcomes the problem of selective report-
ing outcome bias quickly and easily. Prospective 
means prospective. Specifically, you must reg-
ister your trial and “place your bet” on one of 
the recognized trial registers before recruitment 
starts, not when submitting your trial report.
Clinical Trials Submitted to the JID:  
Place Your Bet and Show Us Your Hand
Journal of Investigative Dermatology (2015) 135, 325–327. 
doi:10.1038/jid.2014.478
editorial
326 Journal of Investigative Dermatology (2015), Volume 135 
Rule 2: show us your hand
If you were buying a used car, you would not contemplate a 
purchase without inspecting the service record and viewing 
all the essential items such as applicable taxes, proof of road-
worthiness, and ownership history (Williams, 2010). In the 
same way, you should not “buy” the results of a trial unless 
all of the essential basic items are reported. Complete report-
ing does not necessarily mean good quality, but it is difficult 
to say anything about study quality without seeing exactly 
what was done to whom and how. Not only does full report-
ing permit judgment of study quality and how the results might 
apply to the sorts of patients seen in everyday clinical care, but 
it also permits inclusion of that study in a systematic review 
of all relevant evidence. All trials have a second life in such 
systematic reviews. Systematic reviews of RCTs and appro-
priate meta-analysis of those trials are often considered the 
most informative study type in the evidence-based hierarchy 
of effectiveness studies, yet missing essential information, such 
as description of the intervention, participants, control group, 
and outcomes, frequently hampers the efforts of those who 
produce systematic reviews such as those in the International 
Cochrane Collaboration (http://www.thecochranelibrary.com). 
Thankfully, the CONSORT statement and its various exten-
sions for pragmatic, noninferiority, and cluster trials offer a 
simple checklist for authors to which the JID adheres.
Rule 3: make it a good hand
Although the JID encourages submission of clinical trials that 
are prospectively registered and fully reported, competition to 
publish in our journal means that they also must be something 
special. Small, early, inconclusive proof-of-principle trials are 
less attractive to the JID unless they unlock some key insights 
into mechanisms of diseases. Such clinical trials must be truly 
translational in the way that they are integral to any mecha-
nistic study (see, for example, Papp et al., 2012), rather than 
stuck in as an afterthought to pad out a submission. Clinical 
trials with built-in mechanistic components defining which 
patient groups respond best to treatment fit in very well with 
our journal’s theme of “Progress in Translational Research” 
for 2015. Not all JID trials need to elucidate mechanisms, 
however. Definitive phase III studies that are likely to change 
clinical practice or are newsworthy in some other respect are 
also welcome (see, for example, Joly et al., 2009). Clinical tri-
als evaluating commonly used treatments in which for-profit 
organizations have little interest, such as a head-to-head com-
parison of prednisone and mycophenolate mofetil for pem-
phigus vulgaris, are also welcome (see, for example, Beissert 
et al., 2010). Such trials need not have a “positive” outcome; 
demonstrating equivalence or noninferiority in a planned way 
by estimating likely treatment effects using confidence inter-
vals can be just as informative.
Conclusion
Comparing clinical trials to gambling with cards may sound 
superficial, yet placing a bet is exactly what happens when 
testing a hypothesis, and declaring the results fully and 
honestly is what every good trialist should do. Undertaking 
a clinical trial is a serious professional business that relies on 
the altruistic donation of time and informed risk from patient 
volunteers. Clinical trials are set to remain a backbone of 
experimental design to inform insights into the causes, mech-
anisms, and treatment of skin diseases. We welcome their 
inclusion in this journal.
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